Abstract
Discoidin Domain Receptor 2 (DDR2) is a collagen-activated receptor kinase that, together with integrins, is required for cells to respond to the extracellular matrix. Ddr2 loss-of-function mutations in humans and mice cause severe defects in skeletal growth and development. However, the cellular functions of Ddr2 in bone are not understood. Expression and lineage analysis showed selective expression of Ddr2 at early stages of bone formation in the resting zone and proliferating chondrocytes and periosteum. Consistent with these findings, Ddr2+ cells could differentiate into hypertrophic chondrocytes, osteoblasts, and osteocytes and showed a high degree of colocalization with the skeletal progenitor marker, Gli1. A conditional deletion approach showed a requirement for Ddr2 in Gli1-positive skeletal progenitors and chondrocytes but not mature osteoblasts. Furthermore, Ddr2 knockout in limb bud chondroprogenitors or purified marrow-derived skeletal progenitors inhibited chondrogenic or osteogenic differentiation, respectively. This work establishes a cell-autonomous function for Ddr2 in skeletal progenitors and cartilage and emphasizes the critical role of this collagen receptor in bone development.
Subject terms: Bone, Calcium and phosphate metabolic disorders
Introduction
In addition to its structural function, the collagen-rich extracellular matrix (ECM) of bone has important role in establishing and maintaining cellular organization through control of proliferation, migration, differentiation, and remodeling.1–3 These ECM functions are controlled by receptor-mediated interactions with progenitor cells. Disruption of cell-ECM interactions has been implicated in a wide spectrum of human skeletal disorders, including skeletal dysplasias, chondrodysplasias, osteoarthritis, and osteoporosis.1,4–6 Specific interactions between collagens and skeletal progenitors are mediated by cell-surface receptors, principally β1 integrins and discoidin domain receptors (DDRs).7,8
The principal collagen-binding integrins, α1β1, α2β1, α10β1, and α11β1, are widely expressed in bone cells such as bone marrow precursor cells, chondrocytes, osteoblasts, and osteocytes.9–12 β1 integrin disruption in various bone cell lineages results in skeletal and craniofacial phenotypes of varying severity.13,14 Mice with β1 integrin knockout in Twist2-positive mesenchymal progenitors can still form a mineralized skeleton but die at birth, possibly due to umbilical cord or vascular defects, while disruption in pre-osteoblasts using Osx-Cre results in viable mice with moderate early bone defects that become increasingly milder with age. In contrast, knockout in mature osteoblasts had only minor effects on skeletal phenotype.14 The observation that mineralized tissue can still form in the absence of integrin function suggests the involvement of other collagen receptors.
DDRs are a second class of collagen receptors having important skeletal functions. Both mammalian members of this family, DDR1 and DDR2, represent an unusual class of receptor tyrosine kinases (RTKs) that are activated by triple-helical collagens.8,15,16 Unlike canonical RTKs that bind to soluble ligands, DDRs bind to fibrillar and non-fibrillar collagens with varying specificities and affinities. While both DDR1 and DDR2 bind to type I–III and V fibrillar collagens, only DDR1 binds to the basement membrane type IV collagen and only DDR2 binds to non-fibrillar type X collagen.15–17 Structurally, DDRs consist of a discoidin (DS) domain, followed by a DS-like domain, an extracellular juxtamembrane domain, a transmembrane (TM) domain, an intracellular juxtamembrane domain, and the conserved cytoplasmic tyrosine kinase domain. The DS domain, a 160-amino acid motif in the extracellular region, structurally distinguishes DDRs from other RTKs and is required for recognition and binding to fibrillar collagens.18,19 DDRs recognize a common motif in fibrillar collagens containing the sequence, GVMGFO, that must be in a triple-helical conformation for efficient binding.20 This sequence is distinct from integrin-binding regions of collagen that contain the sequence, GFOGER.21 Human and animal genetic studies indicate that DDR2 is an important regulator of bone growth and skeletal development. DDR2 loss of function mutations in humans causes the rare autosomal recessive growth disorder, spondylo-meta-epiphyseal dysplasia (SMED) with short limbs, and abnormal calcifications (SMED, SL-AC).22–26 This disorder is characterized by disproportionate short stature, short limbs, short broad fingers, abnormal metaphyses and epiphyses, platyspondyly and abnormal calcifications.27,28 Globally, Ddr2-deficient mice share similar phenotypes with SMED, SL-AC patients, including dwarfism, reduced body weight, and skeletal abnormalities characterized by reduced bone mass in axial and appendicular bones, as well as the skull.29–31 Changes in bone mass have been attributed to reduced bone formation in the absence of appreciable defects in osteoclast-mediated bone resorption.30 However, because global Ddr2 deficiency also affects other tissues including gonads, heart, and connective tissue, specific cell-autonomous functions of Ddr2 in the skeleton, if any, cannot be inferred from this work.
Here, we use expression and lineage analysis to identify potential cellular sites of Ddr2 action and employ a conditional deletion approach to establish critical functions for Ddr2 in skeletal progenitor cells and chondrocytes to control cartilage and bone formation.
Results
Ddr2 is expressed in long bone growth plates, periosteum, and bone marrow
Global Ddr2 deficiency is associated with severe skeletal defects. However, no information is available concerning the pattern of Ddr2 expression during bone development. To clarify this issue, we used a LacZ “knock-in” allele of Ddr2 (Ddr2LacZ/+ mice)32 to examine the distribution of Ddr2 expression from embryonic day E9.5 through 3 months (Fig. 1). As shown in whole mounts of X-gal stained embryos, Ddr2 expression was first seen at E11.5 (no staining at E9.5) and continued through fetal and postnatal development. More detailed analysis of sagittal sections from E13.5 embryos and newborns showed strong staining in developing skeletal elements in long bones, ribs, vertebrae, cranial base, and maxillary and mandibular processes (Fig. 1a, c, right panels, panel d). LacZ staining was specific and not observed in wild type Ddr2+/+ embryos (Fig. 1c, left). As shown in whole mounts of developing limbs, staining advanced from proximal regions at E11.5 to distal areas at E13.5 and E18.5 as cartilage and bone formation progressed (Fig. 1e). Cryostat sectioning revealed that this staining was absent from distal mesenchymal condensations of the developing digits but present in more proximal elements specifically in the resting and proliferative zones, but not in the hypertrophic zone, and also in perichondrium (Supplementary Fig. S1). Post-sectioning X-gal staining also detected intense Ddr2 expression in the growth plate, metaphysis and periosteum in newborn and adult mice (Fig. 1f, g). In growth plates, Ddr2 showed a gradient of expression; high in resting zone chondrocytes (R), lower in the proliferating zone (P), and lowest in hypertrophic cells (H). In the metaphysis, staining was in the marrow and on trabecular surfaces (Fig. 1g), but conspicuously absent from cortical and trabecular osteocytes (Supplementary Fig. S2). A similar expression pattern was seen in vertebral growth plates (Fig. 1b). Ddr2 expression was also seen in intervertebral discs with strongest staining in the nucleus pulposus and weaker staining in the annulus fibrosus (Fig. 1b). In summary, initial Ddr2 expression was coincident with the onset of bone formation with the strongest staining in the growth plate resting zone, metaphysis, perichondrium, and periosteum. In contrast, Ddr2 expression was low or undetectable in terminally differentiated cells such as hypertrophic chondrocytes and osteocytes.
Ddr2mer-iCre-mer marks cells at early stages of bone formation that differentiate to hypertrophic chondrocytes, osteoblasts, and osteocytes
The next series of experiments identified the progeny of Ddr2-expressing cells by conducting lineage tracing with Ddr2mer-iCre-mer;R26R-tdTomato mice (see Methods and Supplementary Fig. S3, S4 for development of Ddr2mer-iCre-mer mice). R26R-tdTomato mice have a flanked STOP cassette that interferes with transcription of tdTomato red fluorescent protein. Upon tamoxifen administration, Cre expression driven by the Ddr2 promoter excises the LoxP flanked STOP cassette resulting in tdTomato fluorescent protein only in Ddr2-expressing cells and their progeny. Cre-mediated recombination was induced with daily intragastric tamoxifen (TAM) injections at P1-P4 (Fig. 2a). Long bones were then harvested at P5, P14, and 2 months and cryosections were analyzed by fluorescence microscopy. No fluorescence was observed in the absence of tamoxifen treatment (result not shown). At P5, analysis of the proximal tibia revealed tdTomato fluorescence in a few cells in the growth plate resting zone and strong fluorescence in the perichondrium, metaphysis, and periosteum (Fig. 2b). This distribution is similar to that seen for Ddr2-lacZ staining in Fig. 1; however, in growth plates, the tdTomato labeling was considerably more restricted with only a few cells in upper portion showing fluorescence. In bone marrow, labeling was mainly in the metaphysis in association with trabecular bone. After 2 weeks, tdTomato-labeled cells persisted in the periosteum and bone marrow and expanded throughout resting and proliferative zones constituting the uppermost cells in proximal tibial growth plates. However, they were not detected in the hypertrophic region (Fig. 2c inset). After a 2-month chase, tdTomato-labeled cells contributed to chondrogenic and osteogenic lineages (Fig. 2d). Labeled cells expanded to form long columns of stacked cells beginning from the top of the tibial growth plates and extending to the hypertrophic region, suggesting that Ddr2-expressing cells can form the entire chondrogenic lineage (Fig. 2d, inset 1). TdTomato labeling was also observed on trabecular, endosteal, and periosteal surfaces and in osteocytes. To confirm that tdTomato fluorescence on trabecular surfaces was in osteoblasts, positive co-staining was demonstrated using an anti-OSX antibody (Fig. 2e). This indicates that Ddr2mer-iCre-mer labeled cells also contributed to the osteoblast lineage and eventually osteocytes in trabecular and cortical bones.
Osteoclasts are multinucleated giant cells of the hematopoietic lineage involved in bone resorption during the development and remodeling of the skeleton and during tooth eruption.33 On the basis of cell culture studies, it was previously proposed that Ddr2 is expressed in osteoclasts as well as osteoblasts/osteoprogenitors.34,35 We performed fluorescent-based TRAP staining to mark TRAP+ multinucleated cells on cryostat sections from Ddr2mer-iCre-mer; R26RtdTomato mice. Cre-recombination was induced at birth with four TAM injections, as described in Fig. 2a, and multiple skeletal tissues were examined after 2 weeks. In a long bone, multinucleated TRAP+ cells (cyan) were detected in the subchondral region; however, the spatial distribution of these cells was distinct from that of Ddr2 tdTomato-labeled cells (red), indicating that there is no overlap between TRAP+ osteoclasts and Ddr2 tdTomato-labeled cells or their progeny (Fig. 3a). Based on these results, Ddr2-expressing cells can contribute to chondrogenic and osteogenic lineages but do not form osteoclasts.
Intriguingly, the distribution of Ddr2 in our experiments was reminiscent of that previously reported for Gli1, a mediator of hedgehog signaling and skeletal progenitor cell (SPC) marker. In lineage-tracing experiments, Gli1-positive cells were associated with stem cell populations in cranial sutures, resting and proliferative zone chondrocytes and mesenchymal metaphyseal osteoprogenitors in long bones.36,37 To examine the possible overlap between Ddr2 and Gli1-positive cells, we used lineage analysis to verify the activity of inducible Gli1-CreERT under our experimental conditions by breeding with R26R-tdTomato reporter mice. Newborn Gli1-CreERT;R26R-tdTomato mice were injected with TAM using the same conditions used for Ddr2mer-iCre-mer;R26R-tdTomato mice and analyzed for tdTomato distribution at P14. Similar to previous results,37 tdTomato labeling was detected in periosteum and metaphysis of long bones as well as cranial sutures (not shown). The label was also detected in long bone growth plates, including in most cells in the resting zone and early proliferative zone (Fig. 3b). This pattern is like that seen with Ddr2 labeling, suggesting partial overlap between Ddr2- and Gli1- expressing cells and their progeny. More direct evidence for colocalization of Ddr2 and Gli1 is shown in Fig. 3c using double immunofluorescence labeling of the proximal tibia from P5 mice. Consistent with the Ddr2-LacZ distribution shown in Fig. 1, Ddr2-specific staining (red) was detected in resting and proliferative zones of the growth plate and some marrow cells in the metaphysis. Gli1 (green) showed considerable overlap with Ddr2 particularly in growth plates. Quantitation of Ddr2-Gli1 colocalization is shown in Fig. 3c. Approximately 84 percent of Gli1+ cells in growth plate cells were Ddr2+ while only 17 percent of Gli1+ cells in the metaphysis also contained Ddr2.
Requirement for Ddr2 in specific bone cell populations
From the above results, we conclude that Ddr2 is preferentially localized to the skeleton with initial expression coincident with the onset of bone formation. Ddr2 is expressed at early stages of bone formation in resting and proliferative zone chondrocytes, bone marrow, and periosteum and low or absent from terminally differentiated cells (e.g., hypertrophic chondrocytes and osteocytes). This distribution at least partially overlapped with the SPC marker, Gli1. Furthermore, lineage tracing with Ddr2mer-iCre-mer; R26R-tdTomato mice showed that the progeny of Ddr2-positive cells become hypertrophic chondrocytes, osteoblasts and osteocytes, again consistent with Ddr2 being expressed in the early stages of the bone lineage. However, Ddr2 was also present in metaphyseal osteoprogenitors/osteoblasts on trabecular surfaces, which suggests functions in more mature cells. To assess Ddr2 functions in specific cell populations, we employed a conditional deletion approach. This was necessary both to determine if Ddr2 has cell-autonomous functions in the bone as well as to define the specific cell populations involved. As noted in the Introduction, previous studies with globally Ddr2-deficient mice (Ddr2slie/slie) established the importance of Ddr2 in bone formation.30,31 However, it was not clear from this work whether actions of Ddr2 on the skeleton were direct or indirect. Specifically, Ddr2slie/slie mice have several non-skeletal phenotypes, including gonadal insufficiency and accompanying reductions in levels of circulating sex steroids that could systemically impact bone formation.31 This further emphasizes the importance of using a conditional deletion approach to determine if Ddr2 has cell-autonomous functions. To accomplish this, previously developed Ddr2fl/fl mice32 were crossed with a series of Cre mouse lines to selectively delete Ddr2 in Gli1-positive SPCs, chondrocytes and mature osteoblasts/osteocytes.
Deletion of Ddr2 in Gli1- or Col2a1-positive cells inhibits endochondral bone formation
Gli1-CreERT; Ddr2fl/fl mice were generated and treated with TAM during embryonic development or immediately after birth. In the first case, pregnant dams were given three daily intragastric TAM injections beginning at E12.5 and pups were analyzed at birth (Fig. 4a, b). In the second group, neonates were dosed with TAM at P1-P4 and analyzed after either 2 weeks (Fig. 4d) or 3 months (Fig. 4e–q). Ddr2 knockout during fetal development led to an approximately 15% reduction in growth plate length at birth compared to Ddr2f/f controls (Fig. 4b). This was comparable to the reduction seen in globally Ddr2-deficient newborns (Ddr2slie/slie mice, Fig. 4c). However, there were no obvious changes in bone mineralization (von Kossa-positive area, Fig. 4b, lower panel). Similarly, Gli1-CreERT-mediated Ddr2 knockout in neonates that were analyzed at 2 weeks resulted in an approximately 12% reduction in growth plate length (Fig. 4d). A detailed analysis of the skeletal phenotype of 3 month-old mice allowed us to assess the effects of neonatal Ddr2 inactivation on the young adult skeleton. PCR analysis of genomic DNA extracted from cartilage-containing ear punches was used to demonstrate efficient recombination of the floxed allele in Gli1-CreERT; Ddr2fl/fl mice after TAM injections (Supplementary Fig. S5). Consistent with this result, qRT-PCR analysis of Ddr2 mRNA extracted from whole tibiae showed an 80% reduction in mutant mice, compared with Ddr2fl/fl controls (Fig. 4g). Ddr2 loss in Gli1-expressing cells caused a skeletal dwarfism of similar magnitude to global Ddr2 knockouts (Fig. 4f, h, i). Gli1-CreERT;Ddr2fl/f mice exhibited a significant reduction in the body length both in males and females and a decrease in body weights. The effect of Ddr2 knockout on trabecular and cortical bone was assessed using μCT. Mutant mice displayed a significant reduction in trabecular bone volume (BV/TV) associated with a decrease in trabecular number and thickness and increase in trabecular spacing, compared with Ddr2fl/fl controls (Fig. 4j–n). However, no differences in trabecular or cortical bone mineral density (BMD) were observed, nor was cortical BV/TV reduced (Fig. 4o–q). This phenotype is similar to that seen in Ddr2slie/slie mice.30 These results indicate that Ddr2 functions in Gli1-positive SPCs present during development (E12.5) and in neonates. The consequences of Ddr2 deficiency were first manifested as defects in growth plate-mediated longitudinal growth, but by 3 months also led to defective trabecular, but not cortical bone mass.
Localization studies also detected Ddr2 expression in the resting zone and proliferating chondrocytes. To evaluate the role of Ddr2 in this cell population, Col2a1-Cre; Ddr2fl/fl mice were generated. Col2a1-Cre activity is first detected in head mesenchyme and notochord at E8.5 with subsequent expansion to cartilage rudiments of all endochondral bones by E12. By E14.5 it is active in all cartilage elements, including resting and proliferating zone chondrocytes. However, it has reduced activity in hypertrophic cells and is inactive in osteoblasts.38 Col2a1-Cre; Ddr2fl/fl mice were developed by breeding Col2a1-Cre mice with female Ddr2fl/fl to generate Col2a1-Cre; Ddr2fl/+ heterozygous mice that were then bred with Ddr2fl/fl mice. Conditional knockout mice were born at the expected Mendelian frequency. Gross morphology and skeletal phenotypes of 3 month-old Col2a1-Cre; Ddr2fl/fl mice are shown in Fig. 5 while a more detailed analysis of cartilage during embryonic development and in neonates (P14) is shown in Fig. 6. Analysis of ear cartilage biopsies showed efficient excision of the floxed allele (Supplementary Fig. S6). At 3 months, mutant mice displayed a significant reduction in body length for both males and females (Fig. 5c) and body weight (Fig. 5d). Analysis of trabecular and cortical bone by μCT showed a significant reduction in trabecular BV/TV due to a decrease in trabecular number and thickness and an increase in trabecular spacing, compared with Ddr2fl/fl controls (Fig. 4e–i). However, no changes in trabecular or cortical BMD were observed (Fig. 5j, l). Trabecular bone changes were similar in magnitude to those observed in tamoxifen-treated Gli1-CreERT; Ddr2fl/fl mice. However, Col2a1-Cre; Ddr2fl/fl mice exhibited a mildly reduced cortical bone volume (Fig. 5k). We also compared the expression of several bones and cartilage markers and signaling intermediates in RNA extracted from whole tibias (Fig. 5b, m). As expected, Ddr2 mRNA was reduced by approximately 70 percent in Col2a1-Cre; Ddr2fl/fl mice. Substantial inhibition was also seen for the osteoblast markers, Col1a1 and bone sialoprotein (Ibsp) and the hypertrophic cartilage markers, Col10a1 and Mmp14. Lastly, Ddr2 deficiency reduced expression of the Hedgehog pathway signaling intermediates, Ihh and Gli1.
To further explore the basis for the dwarfism seen in Col2a1-Cre; Ddr2fl/fl mice, endochondral bone formation was examined during embryonic development and in P14 neonates (Fig. 6). Limb buds from control and Col2a1-Cre; Ddr2fl/fl embryos were indistinguishable at E13.5 (result not shown), but by E15.5 clear differences were apparent. By this time, a primary ossification center (POC) containing von Kossa-positive mineral was clearly visible in controls (Fig. 6a; black arrowheads). In contrast, initial bone formation was delayed in mutant mice as evidenced by the persistence of alcian blue-stained cartilage and absence of mineral (Fig. 6a; red arrowheads). By P14, this delay in endochondral ossification led to an approximately 24% reduction in growth plate length in Col2a1-Cre; Ddr2fl/fl mice versus controls (Fig. 6d, e). Linear measurements of individual growth plate histological zones revealed a 30% decrease in the thickness of the proliferative zone in mutant mice (Fig.6f), but no major difference in thickness of the hypertrophic zone (Fig. 6g). To understand the basis for these differences, we assessed chondrocyte proliferation using EdU labeling. For this analysis, mice were intraperitoneally injected with EdU 4 h before sacrifice and cell proliferation was assessed by quantifying EdU-labeled cells in the proliferative zone of growth plates. We found that the number of EdU+ cells in mutant growth plates was ~15% lower than controls (Fig. 6h, i), suggesting deficient chondrocyte proliferation. In contrast, chondrocyte apoptosis measured using a TUNEL assay was not significantly different between Col2a1-Cre; Ddr2fl/fl and control mice (Fig. 6j, k).
The reduced rates of chondrocyte proliferation in Col2a1-Cre; Ddr2fl/fl mice were accompanied by disruption of chondrocyte columnar organization as seen in higher power images (Fig. 6b, boxed region). These changes were also accompanied by altered distribution of type II collagen as measured by immunofluorescence. In control mice, type II collagen immunostaining was detected around chondrocytes and in the interterritorial matrix. However, in Col2a1-Cre; Ddr2fl/fl mice, type II collagen was unevenly distributed with strong staining around chondrocytes and diminished staining in the interterritorial matrix (Fig. 6c, red staining). These abnormalities in matrix organization may directly or indirectly inhibit chondrocyte proliferation and organization, both of which may synergistically contribute to overall shortening in mutant growth plates.
No detectable Ddr2 function in mature osteoblasts
As shown above, knockout of Ddr2 with either Gli1 or Col2a1-Cre results in similar phenotypes, including endochondral growth plate-mediated dwarfism and defects in trabecular bone. In both cases, a clear function for Ddr2 in chondrocyte proliferation is implied. Lineage tracing studies show that Gli1-positive progenitors can form chondrocytes (Fig. 3b), so the Gli1-CreERT would be expected to delete Ddr2 in progenitors as well as chondrocytes37,39 while Col2a1-Cre would directly inactivate Ddr2 in chondrocytes. However, the basis for observed bone defects is less clear. On one hand, Ddr2 could be directly required for osteoblast-mediated bone formation. In fact, we lineage-traced Ddr2-expressing cells to OSX-positive pre-osteoblasts/osteoblasts on select trabecular surfaces (Figs. 1g, 2e) and directly detected Ddr2+ cells by IF on trabecular surfaces (Fig. 3c). Also, Ddr2 is detected in isolated osteoblasts and is necessary for their in vitro differentiation.30,35 Alternatively, there is good evidence that at least a fraction of chondrocytes can transdifferentiate into osteoblasts, thereby potentially carrying the recombined Ddr2 allele into this cell population.40,41 To discriminate between these two possibilities, we inactivated Ddr2 using an osteocalcin promoter-driven Cre (Ocn-Cre), which induces efficient recombination in mature osteoblasts and osteocytes, but not skeletal progenitors or chondrocytes.42 Ocn-Cre induced efficient excision of the floxed Ddr2 allele as measured in vertebrae-containing tail biopsies from Ocn-Cre;Ddr2fl/fl mice (Supplementary Fig. S7) and reduced tibial Ddr2 mRNA by approximately 90 percent (Fig. 7b). Unlike results obtained with Gli1-CreERT or Col2a1-Cre, 3 month Ocn-Cre;Ddr2fl/fl knockout mice were indistinguishable from control littermates. There were no differences in body length or weight (Fig. 7a, c, d) or in trabecular or cortical bone parameters (Fig. 7e–l). From these results, we conclude that Ddr2 is not required for normal bone formation by mature osteoblasts/osteocytes, at least during development and early adult life. Instead, Ddr2 preferentially functions in Gli1-positive skeletal progenitors and chondrocytes.
Requirement for Ddr2 in differentiation of isolated chondroprogenitor and skeletal stem cells
To provide more direct evidence for cell-autonomous functions of Ddr2 in chondroprogenitors, micromass cultures were established from Ddr2fl/fl embryo limb buds at E12.5.43,44 After transduction with adeno-Cre or adeno-LacZ (control), cells were grown in chondrogenic medium (see Methods). The efficiency of Ddr2 knockout was confirmed using qRT-PCR (approx. 90 percent decrease in Ddr2 mRNA, Fig. 8b). Alcian blue staining of micromass cultures showed a dramatic decrease in cartilage nodule formation in adeno-Cre-infected cells (Fig. 8a, top panels). Samples were also stained with eosin to visualize total protein; Ddr2-deficient cells were shown to have a diffuse ECM in which cells failed to aggregate (bottom panels). To determine if Ddr2 inactivation reduced cell number, the DNA content of micromass cultures was measured. However, no significant differences were noted between control and adeno-Cre infected cells (Fig. 8c).
Consistent with Ddr2 being important for chondrocyte differentiation, expression of the chondrocyte markers, Sox9, Col2a1, Aggrecan, Comp, and Mmp13 were all significantly downregulated (Fig. 8d). Like in vivo results using Col2a1-Cre; Ddr2fl/fl mice (Fig. 5m), knockout of Ddr2 in micromass cultures also inhibited expression of the hedgehog signaling intermediates, Ihh, Gli1 and Ptch1 (Fig. 8e–g).
Ddr2-LacZ localization studies identified Ddr2 expression in the metaphyseal bone marrow, one of the regions known to contain SPCs.37 To determine whether Ddr2 can affect lineage allocation and differentiation of marrow-derived SPCs, we sorted non-hematopoietic (CD45-,Ter119-), CD140a+CD51+ cells from the bone marrow of Ddr2fl/fl mice (Fig. 9a). This cell population has a number of SPC properties; it contains most of the colony forming activity of marrow, has high self-renewal capacity, gives rise to BM stromal cells and bone, supports hematopoiesis and exhibits multipotency (forms osteoblasts, adipocytes and chondrocytes).45 Gene expression analysis showed enrichment of Ddr2 in CD140a+CD51+ MSCs along with other stem cells markers including Gli1, LepR, Sca1 and Nestin when compared with total nucleated cells (Fig. 9b). To evaluate the role of Ddr2 in this population, cells were transduced with adeno-Cre or adeno-LacZ and analyzed for SC properties and multipotency. Adeno-Cre treatment abolished most Ddr2 expression (95 percent inhibition, Fig. 9f) and reduced lineage allocation of fibroblast colony forming units (CFU-Fs) to osteoblasts (CFU-Ob) without affecting total CFU-Fs (Fig. 9c–e). Similarly, the bone markers, Bglap, Ibsp, and Runx2 were all reduced. These results indicate Ddr2 is expressed in a skeletal progenitor-enriched cell population and is required for osteoblast differentiation of these cells. They are consistent with in vivo studies showing that Ddr2 functions in progenitor populations to control the growth and differentiation of bone.
Discussion
Although it is widely appreciated that the ECM provides important cues for the growth and development of the skeleton, the relative contribution of different collagen receptors to this process is not well-understood. Here we show the fibrillar collagen receptor, DDR2, to be preferentially expressed in resting and proliferating zone chondrocytes and periosteum where it has important cell-autonomous functions necessary for chondrocyte organization and growth as well as subsequent bone formation. Conditional deletion studies revealed a requirement for Ddr2 in Gli1-positive skeletal progenitors and chondrocytes, but no obvious activity in mature osteoblasts. Consistent with a function in progenitor cells, we find that disruption of Ddr2 in limb bud chondroprogenitors and marrow skeletal progenitors blocks chondrocyte and osteoblast differentiation, respectively. These studies greatly expand our understanding of the cellular functions of this important bone-associated collagen receptor and suggest potential DDR2-mediated strategies for regulating bone formation and regeneration.
Previous studies detected DDR2 in a wide range of mesenchyme-derived tissues including skin, lung, heart, muscle, tooth mesenchyme, and periodontal ligament.32,46,47 However, its distribution during development had not been systematically examined. Using a combination of expression studies with Ddr2LacZ/+ mice and lineage tracing, we showed that Ddr2 is preferentially expressed in resting and proliferating chondrocytes, periosteum and metaphysis. Furthermore, progeny of Ddr2-positive cells can form hypertrophic chondrocytes, osteoblasts and osteocytes, consistent with Ddr2 being expressed in progenitor populations. The earliest Ddr2 expression was detected at E11.5 and, by E13.5, it was present in all skeletal elements, including growth plate cartilage, metaphyses, and periosteum. This expression pattern persisted into adult life. More detailed analysis showed that, for each bone cell lineage, Ddr2 was restricted to earlier developmental stages. Thus, growth plate expression was restricted to the resting zone and some proliferating chondrocytes, but low or absent from the hypertrophic zone, while in metaphyseal bone, expression was in the marrow and on the trabecular surface and periosteum of cortical bone, but not in osteocytes. This distribution is markedly different from the collagen-binding integrins, α1β1, α2β1, and α11β1 that are broadly expressed in many tissues. However, the distribution of Ddr2 may partially overlap with α10β1 integrin, which is preferentially expressed in chondrocytes.48–50
Lineage tracing analysis provided further evidence for preferential Ddr2 expression at early stages in the bone lineage, possibly in SPCs. TAM injection of neonatal Ddr2mer-iCre-mer;R26R-tdTomato mice initially labeled cells in the growth plate resting zone, perichondrium, trabecular surfaces, and periosteum in a pattern that was similar to although considerably weaker than that seen when LacZ staining was examined in Ddr2LacZ/+ mice. The more restricted tdTomato staining may be due to low availability of TAM to cartilage or low efficiency of Cre-mediated recombination in Ddr2mer-iCre-mer;R26R-tdTomato mice. Nevertheless, at early times after TAM administration, tdTomato immunofluorescence was conspicuously absent from terminally differentiated bone cells including hypertrophic chondrocytes and osteocytes. These cells only became labeled after a 2-month chase period as would be expected if Ddr2 was expressed in chondrocytes and osteoprogenitors that were precursors to hypertrophic chondrocytes and osteoblasts.
Consistent with localization studies, conditional deletion analysis provided strong evidence for selective activity of Ddr2 in progenitor populations and chondrocytes. The mice selected for these studies were previously shown to have strong Cre activity in skeletal progenitors (Gli1-CreERT), chondrocytes (Col2a1-Cre) or mature osteoblasts/osteocytes (Ocn-Cre). For Gli1-CreERT, lineage tracing previously showed that cells marked with this Cre are a major source of skeletal progenitors during embryonic development and in adults.37 Gli1+ cells labeled during embryonic stages give rise to most osteoblasts, chondrocytes, marrow adipocytes and stroma. A separate pool of mesenchymal stem cell-like Gli1+ cells were identified beneath the growth plate (termed “metaphyseal mesenchymal progenitors”) and shown to be essential for trabecular bone formation in young mice. We compared the distribution of tdTomato in Gli1-CreERT;R26R-tdTomato mice with Ddr2mer-iCre-mer;R26R-tdTomato mice and found considerable overlap. Furthermore, immunofluorescence microscopy showed strong colocalization of Ddr2 and Gli1 in resting and proliferating zone chondrocytes and select metaphyseal cells of the proximal tibia, which is consistent with Ddr2 functioning in Gli1-positive SPCs. The Col2a1-Cre we used is expressed early in development beginning at E8.5 and present in all endochondral bone rudiments by E12.5.38 Lineage tracing using this Cre showed it marks growth plate cartilage and perichondrium by E12.5 and, subsequently, most osteoblasts and marrow stromal cells of endochondral bone, consistent with it being expressed in chondrocytes, some of which can transdifferentiate into osteoblasts.51
The phenotypes of TAM-treated Gli1-CreERT;Ddr2fl/fl mice and Col2a1-Cre; Ddr2fl/fl mice were remarkably similar. Gli1-CreERT;Ddr2fl/fl mice exhibited severe defects in tibial growth plates regardless of whether Ddr2 was inactivated in embryos (TAM treatment at E12.5-14.5) and analyzed at birth or in neonates (TAM treatment at P1-4) and analyzed at P14. In both cases, growth plate length was reduced from 15-20 percent, comparable to what was seen in globally Ddr2-deficient mice. Similarly, growth plate length was reduced by approximately 24% in Col2a1-Cre; Ddr2fl/fl mice at P14. Gli1-CreERT;Ddr2fl/fl and Col2a1-Cre; Ddr2fl/fl mice also had similar bone phenotypes when measured at 3 months. In both cases, Ddr2 knockout reduced trabecular BV/TV by 50%–55% in males and by approximately 40% in females. The only difference noted between Gli1-CreERT;Ddr2fl/fl and Col2a1-Cre; Ddr2fl/fl mice was a small decrease in cortical BV/TV in the latter group. A similar decrease in cortical bone was also previously observed in globally Ddr2-deficient mice.30 This difference may be the consequence of reduced efficiency of the Gli1-CreERT or be explained by activity of Col2a1-Cre at early embryonic stages versus Gli1-CreERT, which was not activated by TAM until P1-4. In contrast to these results, Ocn-Cre; Ddr2fl/fl mice had no detectable bone defects; mice were of normal length and weight and trabecular and cortical bone parameters were indistinguishable from wild type controls.
Further evidence for Ddr2 having cell-autonomous functions in skeletal progenitor populations came from cell culture studies. Ddr2 knockout in embryonic limb bud chondroprogenitor cells or PDGFRα+/CD51+ SPCs purified from marrow prevented chondrocyte or osteoblast differentiation, respectively. In limb bud micromass cultures, Ddr2 knockout greatly reduced proteoglycan production as measured by Alcian blue staining, prevented cell aggregation and blocked expression of chondrocyte markers and Hedgehog signaling intermediates. Although Ddr2 deficiency reduced cell proliferation in vivo, results from micromass cultures cannot be explained by a proliferation defect since total cell number as reflect by DNA content was not significantly reduced in with Ddr2 deficiency. Instead, our results suggest that Ddr2 is necessary for limb bud cells to aggregate, which is required for subsequent differentiation. Similarly, knockout of Ddr2 in PDGFRα+/CD51+ SPCs led to a dramatic decrease in lineage allocation of cell clones to osteoblasts without affecting total CFUs.
One unresolved issue in the above studies is the degree to which Ddr2 functions in SPCs and is a marker for this cell type versus having more restricted functions in cartilage. While studies with Ddr2LacZ/+ mice showed expression in resting zone chondrocytes, periosteum and marrow, regions known to contain SPCs, Ddr2 was not expressed in early mesenchymal condensations during limb development (e.g., compare lack of expression in distal versus proximal limb elements at E13.5, Supplementary Fig. S1). Also, although lineage tracing in Ddr2mer-iCre-mer;R26R-tdTomato mice showed initial tdTomato labeling of resting and proliferative zone chondrocytes, periosteum, and metaphysis with subsequent lineage tracing of label into hypertrophic chondrocytes, osteoblasts, and osteocytes, the number of tdTomato cells did not increase over time as would be expected if it were marking an SPC population capable of self-renewal. While it could be argued that the colocalization of Ddr2 with Gli1 and strong skeletal phenotype of tamoxifen-treated Gli1-CreERT;Ddr2fl/fl mice is consistent with Ddr2 functioning in Gli1-positive SPCs, it cannot be resolved from our studies if Ddr2 functions in SPCs or in the progeny of these cells, since they are progenitors for chondrocytes and osteoblasts. Lastly, the demonstrated requirement for Ddr2 in the differentiation of limb bud micromass cultures or CD140a+CD51+ MSCs both represent results of cell culture assays for SPC properties and do not necessarily mimic in vivo SPC behavior. To resolve whether Ddr2 actually has a SPC function in vivo will require more detailed analysis, including lineage tracing studies at multiple time points and extensive single cell transcriptome analysis.
The mechanistic basis for the observed defects in cartilage and bone formation associated with Ddr2 deficiency are not currently understood. From our studies, it is clear that Ddr2 affects the behavior of skeletal lineage cells at relatively early stages in their lineage, but beyond this little is known. The more detailed examination of growth plate development conducted in Col2a1-Cre;Ddr2fl/fl mice revealed that initial bony collar formation was delayed in E15.5 embryos. Also, the subsequent reduction in proliferative zone length and dwarfism of Ddr2-deficient mice was explained, in part, by an inhibition of chondrocyte proliferation in the absence of changes in apoptosis. This inhibition was accompanied by altered type 2 collagen matrix distribution and abnormal orientation of chondrocytes of resting and proliferating zone chondrocytes. Similar changes in chondrocyte proliferation and matrix organization were previously reported in globally Ddr2-deficient mice and in SMED-SL-AC patients, respectively,27,52 and may be related to the ability of DDR2 to affect collagen fibril formation either by altering fibrillogenesis or matrix remodeling.53,54 Interestingly, knockout of β1 integrins in cartilage also alters chondrocyte organization and matrix deposition, and there is some evidence that DDR2 and β1 integrins functionally interact.55,56
Unlike integrins, DDR2 signaling pathways have not been extensively studied. On binding fibrillar collagens, DDR2 is auto phosphorylated with a characteristically slow time course that persists for several hours. This is accompanied by activation of several down-stream events including binding of Src and subsequent activation of the ERK-MAPK pathway.46 The importance of MAPK activation is emphasized by the observation that Ddr2 overexpression can stimulate MAPK-mediated phosphorylation of RUNX2 and PPARγ transcription factors leading to increased osteoblast differentiation and decreased adipogenesis by mesenchymal cells. Consistent with these findings, defects in osteoblast differentiation seen in calvarial cells from Ddr2-deficient mice can be rescued by a phosphomimetic RUNX2 mutant (Runx2-S301ES319E) that does not require phosphorylation for optimal activity. In contrast, a RUNX2 mutant that cannot be phosphorylated (Runx-S301A,S319A) is not affected by Ddr2 status.30 Earlier studies by our group examined the importance of MAPK signaling in bone formation in vivo using transgenic mice selectively expressing a constitutively-active or dominant-negative form of the MAPK intermediate, MEK1, in bone.57 Examination of bone formation in these mice revealed that inhibition of MAPK signaling at E15.5 delayed initial bony collar formation. This result is similar to what we observed in Col2a1-Cre; Ddr2fl/fl mice where the initial bone formation was also delayed at this time and is consistent with Ddr2 deficiency being accompanied by a defect in MAPK signaling.
Insight into pathways important for DDR2 signaling may be also gained from gene expression analysis that was conducted on bones from control and Col2a1-Cre; Ddr2fl/fl mice. In addition to reducing cartilage and bone marker mRNAs, loss of Ddr2 was associated with reduced expression of Hh pathway signaling intermediates including Ihh and Gli1. Similar changes in gene expression were noted with Ddr2 loss in micromass cultures, which suggests it can regulate Hh signaling. In a recent report, cartilage deficiency of the other mammalian DDR homolog, discoidin domain receptor 1, was also associated with defective Hh signaling suggesting that this may be a common pathway regulated by this class of receptors.58
Materials and methods
Mice
Ddr2slie/slie mice carrying a spontaneous 150-kb deletion mutation of Ddr2 exons 1-17 resulting in a null allele was obtained from the Jackson Labs and bred into a C57BL6 background for at least ten generations.31 Homozygous (Ddr2 slie/slie) mice were obtained from intercrossing heterozygous (Ddr2slie/+) mice. Ddr2LacZ/+ and Ddr2fl/fl mice were generated from “knockout-first” ES cell clone Ddr2tm1a(EUCOMM)Wtsi(EPD0607__B01; European Mutant Mouse Repository) (https://www.eummcr.org). Ddr2-LacZ knock-in mice were developed by crossing founder mice harboring the Frt- flanked β-galactosidase (LacZ)-neo cassette with constitutive Sox2-Cre mice while Ddr2fl/fl mice were generated by crossing founder mice harboring the loxP- flanked coding exon 8 (exon 8) with the FLPo delete mice (described in reference32). Ddr2fl/fl mice were backcrossed onto C57BL/6 for at least six generations.
Ddr2mer-iCre-mer mice harboring MerCreMer cassette knocked in-frame into exon 2 of the Ddr2 locus were developed using a targeting strategy similar to that reported previously29, with changes based on targeting exon 2 of the mouse Ddr2 gene (see Supplementary Figs. 1 and 2). Briefly, the 4.4 kb left homology arm (LHA) was amplified using primers 5’-AACGCGTTGGATCTGGAGTCTGCAGCCCACCGACAA-3’ and 5’-GGAGATGCAGGCCATGTTGCCCCAACACCTCCCATT-3’. The 4.0 kb right homology arm (RHA) was amplified using primers 5’-ACTCCACAGTGCCAAAGATGGTGCCTGAAGCCATGA-3’ and 5’-GCGGCCGGGTTCCCAAGATCTCAGGTAAGCTTTTGT-3’. The arms were cloned individually into pCR-BluntII-TOPO (Life Technologies), selecting the desired orientation by restriction enzyme screening. The MerCreMer-neoR cassette was excised from the vector, pBKSII-MerCreMer-Mcl-neo (kindly provided by Dr. Sylvia Evans, UCSD), by NotI and partial NcoI (cutting only at sequence position 60) digestion. This NcoI/NotI MerCreMer-neoR cassette was ligated into the MluI/NotI sites of the pCR-BluntII-LHA construct, using an MluI-HinDIII-NcoI linker adapter (annealed 5’-CGCGTAAGCTTCCAC-3’ and 5’-CATGGTGGAAGCTTA-3’). The resulting construct was digested with NotI, dephosphorylated, and ligated to the EagI insert of pCR-BluntII-RHA to produce pCR-BluntII-LHA-MerCreMer-neoR-RHA; the correct orientation was selected by restriction enzyme screening. To provide negative selection, a diphtheria toxin A coding cassette (PspOMI/NotI fragment, kindly provided by Dr. Ju Chen, UCSD) was then ligated into the dephosphorylated NotI site of pCR-BluntII-LHA-MerCreMer-neoR-RHA, ensuring that the preserved NotI site was distal to the RHA. The resulting targeting vector was linearized with NotI, electroporated into 129R1 mouse embryonic stem cells, and individual G418-resistant clones selected. Clones were screened initially by PCR, and the positive clones were verified by Southern blot, using KpnI digestion with probe C and BamHI digestion with probe D (Supplementary Fig. 2a). One targeted clone was microinjected into C57Bl/6 blastocysts, and these blastocysts were implanted into pseudopregnant female hosts. Chimeric pups were bred and agouti pups screened for the targeted mutation. The neomycin resistance (neoR) cassette was removed by breeding with a FLPe deleter mouse (kindly provided by Dr. Ju Chen, UCSD). The resulting mouse was backcrossed into C57Bl/6 for at least ten generations. The Transgenic Core and Embryonic Stem Cell shared resource at UCSD assisted in the production of this knockin mouse. Validation of MerCreMer protein expression in cardiac fibroblasts from a tamoxifen-treated a positive Ddr2mer-iCre-mer mouse is shown in Supplementary Fig. 2bRosa26-CAG-loxP-stop-loxP-tdTomato (Ai14: R26R-tdTomato) mice, a gift from Dr. Noriaki Ono (U. Michigan), have been described previously.59 To obtain Ddr2mer-iCre-mer; R26RtdTomato reporter mice, we crossed Ddr2mer-iCre-mer heterozygous mice with the Ai14:R26RtdTomato line.
Ddr2 tissue-specific conditional knockouts were generated by crossing mice carrying the Ddr2 floxed allele with the following Cre driver mouse lines: Gli1-CreERT (gift from Dr. Yuji Mishina, U. Michigan), Col2a1-Cre (gift from Dr. Ernestina Schipani, U Michigan) and Ocn-Cre (gift from Dr. Kurt Hankenson (U. Michigan).38,42,60 Most mice used in our experiments were analyzed on C57BL/J6 background, except Col2a1-Cre; Ddr2fl/fl mice were analyzed on mixed background. All mice were housed under a 12 h light cycle in compliance with the Guidelines for the Care and Use of Animals for Scientific Research. All protocols for mouse experiments were approved by the Institutional Animal Care and Use Committee of the University of Michigan.
Genotyping
Production and genotyping of Col2a1-Cre, Gli1-CreERT, Ocn-Cre and Ai14: R26R-tdTomato mice have been described previously.38,42,59,60 Genomic DNA was prepared from tail snips or ear punches using DNA REDExtract-N-Amp™ Tissue PCR Kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. Tissue samples were incubated in extraction buffer for 10–30 min at room temperature (RT), heated at 95 °C for 3 min followed by neutralization. Polymerase chain reaction (PCR) analysis was then used to genotype mice. Information about primers used for genotyping Ddr2fl/f, Ddr2LacZ/+ and Ddr2mer-iCre-mer mice is presented in Supplementary Materials, Table 1. The genotyping of Ddr2slie/slie mice was performed using qRT-PCR using conditions defined by Jackson Labs.
Tamoxifen administration
Tamoxifen-free base (Sigma T5648) was dissolved in absolute ethanol. The tamoxifen solution was mixed with corn oil (Sigma C8267) and vortexed thoroughly to prepare a stock solution of 40 mg·mL−1. For administration of tamoxifen by oral gavage, 20 mg·mL−1 progesterone (Sigma P3972) was added to the tamoxifen stock solution. An appropriate volume of tamoxifen-progesterone solution was administrated by oral gavage to pregnant females for 3 days beginning from E12.5 and pups were harvested at birth. For newborn mice, four daily tamoxifen injections were administrated intragastrically using a 29 G needle (BD insulin syringe). The dosing conditions used were previously described.61
Micro-computed tomography analysis
A total of 20 tibiae collected from 3 month-old male and female mice (n = 10/gender) were fixed in 10% formalin at 4 °C overnight. Tibiae were scanned using a Scanco Model 100 (Scanco Medical) to evaluate bone parameters of proximal trabecular bone and mid-shaft cortical bone. Scan settings were as follows: voxel size of 12 μm, 70 kVp, and integration time of 500 ms. For the trabecular bone of proximal tibia, a contouring tool was used to trace the trabecular bone in 30 CT slices below the growth plate to evaluate bone volume fraction (Trab. BV/TV; Bone volume/ Total volume), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular bone mineral density (Trab. BMD). The analysis of the cortical bone included 30 CT slices at the tibial mid-shaft to assess bone volume fraction (Cort. BV/TV) and cortical bone mineral density (Cort. BMD). The mean BMD value is in units of mg HA per ccm. A threshold of 180 for tibial trabecular and 280 for cortical bone analysis was used throughout the whole study. The mouse genotype was not specified during μCT analysis to avoid examiner bias.
LacZ (β-galactosidase) staining and detection
LacZ staining of heterozygous Ddr2-LacZ (Ddr2LacZ/+) mice was performed as previously described.62 Samples were fixed in 2% paraformaldehyde and 0.2% glutaraldehyde in 0.1 mol·L−1 phosphate buffer pH 7.4 at 4 °C. For LacZ staining, samples were incubated in a freshly prepared X-gal solution containing X-gal substrate (UltraPure, X-Gal, Invitrogen) for overnight at 37 °C. For cryostat sections, samples were decalcified with 20% ethylenediaminetetracetic acid (EDTA) (pH 7.2) from 3 days to 2 weeks according to the mouse age, embedded in optimal cutting temperature compound (Tissue-Tek), cryosectioned at 10–12 μm thickness, subjected to LacZ staining and counterstained with Vector Nuclear Fast Red.
Histology and immunostaining
Long bones were fixed in 4% paraformaldehyde (PFA) for 48 h at 4 °C. Specimens were decalcified in 10% EDTA (pH 7.2) (Fisher, S316-212) and were then processed for paraffin embedding. Specimens were sectioned at 5 μm using a microtome, de-paraffinized and hydrated in ethanol series and in distilled water. For histological analysis, the sections were stained with hematoxylin and eosin (H&E) according to the standard procedures. For Safranin O staining, sections were stained with Safranin O (0.1% Safranin O) for 20 min and Fast Green (0.02% Fast Green FCF) for 5 min. For von Kossa staining, sections were stained with 5% silver nitrate solution for 1 h under strong light, rinsed with distilled water, and stained with 5% sodium thiosulfate solution for 5 min, and counterstained with nuclear fast red staining for 5 min. For immunofluorescence, sections were subjected to heat-induced antigen retrieval using citrate buffer (target retrieval solution, Dako) following the manufacturer instructions, washed with PBS and then incubated with blocking buffer containing 2%–5% normal donkey serum, 1% bovine serum albumin (BSA), 0.01% tween in 1 BSP for 1 h at RT in a humid box. After blocking, the sections were then incubated at 4 °C overnight using Anti-COL2 (1:100, ab34712, Abcam), Anti-DDR2 (1:200 LS B15752, LSBio) and Anti-Gli1 (1:100, Santa Cruz SC-515751). The sections were incubated with species-matched secondary antibody (Invitrogen) for 1 h at RT. The slides were mounted using ProLong™ Gold Antifade Mountant with DAPI (Life technologies) for cell nuclei staining. For colocalization studies in Ddr2mer-iCre-mer; R26RtdTomato reporter mice, frozen sections were prepared as described for LacZ studies, stained with anti-OSX antibody and approriate secondary antibodies before analysis by immunofluorescence microscopy using a Nikon 50i microscope.
Proliferation and apoptosis assay
For proliferation, mice were injected intraperitoneally with 5-ethynyl-2’-deoxyuridine (component A, Invitrogen, # C10337) and sacrificed 4 h after injection. EdU-labeled cells were detected using Click-iT® EdU Alexa Fluor® 488 Imaging Kit (Invitrogen, # C10337) according to the manufacture instruction. For apoptosis, Click-iT® Plus TUNEL assay was used on tissue sections following the manufacture instructions (Invitrogen, # C10618). The sections were mounted with DAPI (Life technologies).
Fluorescence-based ELF97 TRAP for osteoclasts
Tissue sections were stained with tartrate-resistant acid phosphatase (TRAP) using an ELF97 endogenous phosphatase detection kit (Invitrogen) combined with reagents from an acid phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich). Briefly, ELF97 endogenous phosphatase substrate was added to a mixture of 11 mmol·L−1 sodium nitrate, 112 mmol·L−1 sodium acetate, and 76 mmol·L−1 sodium tartrate solutions in ddH2O. Sections were incubated with the TRAP mixture in a dark humid chamber for 15 min at RT, washed with PBS, mounted with aqueous medium.
Micromass culture for chondrogenesis
Micromass culture was performed according a published protocol.44 Primary chondroprogenitors were isolated from E12-limb buds of Ddr2fllfl embryos. Briefly, limb buds were harvested under sterile conditions and digested in 1 U·mL−1 dispase II-containing solution (dispase II enzyme from Gibco) for 40 min at 37 °C. The cells in the digestion solution were spun down, resuspended in DMEM F12 media plus 10% FBS (growth medium), and filtered using a 40 μ cell strainer. The cell density and volume was adjusted to have 2 × 107 cells per mL. The cells were transfected with Ad5-CMV-LacZ (AdLacZ) (control) or Ad5-CMV-CRE (AdCre) adenoviruses at MOI of 100. The adenoviruses were prepared at a titer of 1 × 1011 pfu per mL and obtained from the Vector core, University of Michigan. Cells were grown for 3 day in growth medium, transferred to differentiation medium (growth medium supplemented with 1 mmol·L−1 β-glycerol phosphate and 0.25 mmol·L−1 ascorbate) and grown for an additional 8 day before analysis. For alcian blue staining, the cultured cells were fixed with 3.7% formalin in BPS, washed with BPS and 0.2 mol·L−1 HCl for 5 min and stained with alcian blue staining as described previously.44
Flow cytometry/FACS analysis
Mouse tibiae were flushed using a 21 G needle to collect BM cells into digestion buffer containing 2 mg·mL−1 collagenase IV/ 3 mg·mL−1 dispase in 1X PBS. Multiple cycles of digestion with agitation were performed at 37 °C (7 min each) to obtain single cell suspension. Single cell suspensions were transferred into DMEM medium containing 10% calf serum and maintained at 4 °C until the rest of the tissue was completely digested. Red blood cells were lysed in 1:1 NH4Cl hypotonic solution. Cells were filtered into clean 50 mL conical tubes, centrifuged at 1 100 r·min−1, 4 °C, for 10 min, resuspended in staining buffer (2 mmol·L−1 EDTA, 0.5% BSA in 1X PBS), and transferred to FACS tubes for staining. The following cell-surface markers were used: For exclusion hematopoietic cells: TER119-AF700 (Biolegend, Clone:TER119, 1:100) and CD45-APC-Cy7 (Biolegend, Clone:30-F11, 1:200). For identifying MSCs: CD140a-Biostin (Biolegend, Clone:APA5, 1:200) and CD51-PE (Biolegend, clone:RMV-7, 1:200). MSCs (CD45-Ter119-CD31-PDGFRα+ CD51+) were used for colony and gene expression assays.
Colony forming unit (CFU) assays
CFU assays were performed with briefly cultured MSCs from bone marrow (CD45-Ter119-CD31-PDGFRα+ CD51+). Cells were seeded at a density of 1 × 103 cells per well in 6 well plates and maintained in DMEM/10% FBS medium at 37 °C with 5% CO2. The medium was changed every 2–3 days. After 14 days, cells were stained with Giemsa Stain Solution (Sigma #R03055) to detect CFU-Fibroblasts. For CFU-Ob detection, cells were grown in 50 μg·mL−1 ascorbic acid and 10 mmol·L−1 β-glycerophosphate for 14 days. Cultures were incubated at room temperature in 2% Alizarin Red S (pH 4.2 with 10% ammonium hydroxide) for 0.5 h.
Gene expression analysis
Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s protocol. Total RNA (1 μg) was used to make complementary DNA (cDNA) using TaqMan™ reverse transcription reagents (Applied Biosystems). mRNA levels were determined using quantitative real-time PCR (qRT-PCR) with TaqMan probes on an ABI 7500 thermocycler (Applied BioSystems). Gapdh, the housekeeping gene, was used to normalize the expression of levels of target genes.
Statistical analysis
All data were analyzed using GraphPad Prism software (version 6.Oe, La Jolla, CA, USA), and results were reported as mean ± SD. A samples size of 20 (n = 20, n = 10/gender) was used for microCT analysis and at least three mice were used for histological analysis. Two-tailed unpaired t-test was used to analyze the difference between the controls and mutant groups. A probability was considered statistically significant when *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.000 1. ns. not significant. Results are presented as mean ± SD or SEM as indicated.
Supplementary information
Acknowledgements
This work was supported by a scholarship from the Ministry of Higher Education and Scientific Research, Libyan Transitional Government (FFM), a scholarship from King Saud University (AB), NIH/NIDCR grants DE11723, DE029012, DE029465, Department of Defense grant PR190899, research funds from the Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry (to RTF) and the Michigan Musculoskeletal Health Core Center ((NIH/NIAMS P30 AR069620).
Author contributions
F.M., C.G., A.B., and S.H. conducted experiments, R.C. and B.G. developed Ddr2mer-iCre-mer mice; N.O. assisted with lineage tracing studies; F.M., C.G., D.L., S.H., and R.T.F. conducted all data analysis; F.M. and R.T.F. wrote the manuscript. All authors critically reviewed the manuscript.
Competing interests
The authors declare no competing interests.
Supplementary information
The online version contains supplementary material available at 10.1038/s41413-021-00182-w.
References
- 1.Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R. Toward a molecular understanding of skeletal development. Cell. 1995;80:371–378. doi: 10.1016/0092-8674(95)90487-5. [DOI] [PubMed] [Google Scholar]
- 2.Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 2011;209:139–151. doi: 10.1530/JOE-10-0377. [DOI] [PubMed] [Google Scholar]
- 3.Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev. Biol. 2010;341:126–140. doi: 10.1016/j.ydbio.2009.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Kuivaniemi H, Tromp G, Prockop DJ. Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. Hum. Mutat. 1997;9:300–315. doi: 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
- 5.Lu, P., Takai, K., Weaver, V. M. & Werb, Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol.3, a005058 (2011). [DOI] [PMC free article] [PubMed]
- 6.Velleman SG. The role of the extracellular matrix in skeletal development. Poult. Sci. 2000;79:985–989. doi: 10.1093/ps/79.7.985. [DOI] [PubMed] [Google Scholar]
- 7.Harburger DS, Calderwood DA. Integrin signalling at a glance. J. Cell Sci. 2009;122:159–163. doi: 10.1242/jcs.018093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Leitinger B, Hohenester E. Mammalian collagen receptors. Matrix Biol. 2007;26:146–155. doi: 10.1016/j.matbio.2006.10.007. [DOI] [PubMed] [Google Scholar]
- 9.Hughes DE, Salter DM, Dedhar S, Simpson R. Integrin expression in human bone. J. Bone Min. Res. 1993;8:527–533. doi: 10.1002/jbmr.5650080503. [DOI] [PubMed] [Google Scholar]
- 10.Gronthos S, Simmons PJ, Graves SE, Robey PG. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone. 2001;28:174–181. doi: 10.1016/s8756-3282(00)00424-5. [DOI] [PubMed] [Google Scholar]
- 11.Nesbitt S, Nesbit A, Helfrich M, Horton M. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J. Biol. Chem. 1993;268:16737–16745. [PubMed] [Google Scholar]
- 12.Leitinger B. Transmembrane collagen receptors. Annu. Rev. Cell Dev. Biol. 2011;27:265–290. doi: 10.1146/annurev-cellbio-092910-154013. [DOI] [PubMed] [Google Scholar]
- 13.Zimmerman D, Jin F, Leboy P, Hardy S, Damsky C. Impaired bone formation in transgenic mice resulting from altered integrin function in osteoblasts. Dev. Biol. 2000;220:2–15. doi: 10.1006/dbio.2000.9633. [DOI] [PubMed] [Google Scholar]
- 14.Shekaran A, et al. The effect of conditional inactivation of beta 1 integrins using twist 2 Cre, Osterix Cre and osteocalcin Cre lines on skeletal phenotype. Bone. 2014;68:131–141. doi: 10.1016/j.bone.2014.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Shrivastava A, et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol. Cell. 1997;1:25–34. doi: 10.1016/s1097-2765(00)80004-0. [DOI] [PubMed] [Google Scholar]
- 16.Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell. 1997;1:13–23. doi: 10.1016/s1097-2765(00)80003-9. [DOI] [PubMed] [Google Scholar]
- 17.Leitinger B, Kwan AP. The discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol. 2006;25:355–364. doi: 10.1016/j.matbio.2006.05.006. [DOI] [PubMed] [Google Scholar]
- 18.Leitinger B. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2. J. Biol. Chem. 2003;278:16761–16769. doi: 10.1074/jbc.M301370200. [DOI] [PubMed] [Google Scholar]
- 19.Leitinger B, Steplewski A, Fertala A. The D2 period of collagen II contains a specific binding site for the human discoidin domain receptor, DDR2. J. Mol. Biol. 2004;344:993–1003. doi: 10.1016/j.jmb.2004.09.089. [DOI] [PubMed] [Google Scholar]
- 20.Konitsiotis AD, et al. Characterization of high affinity binding motifs for the discoidin domain receptor DDR2 in collagen. J. Biol. Chem. 2008;283:6861–6868. doi: 10.1074/jbc.M709290200. [DOI] [PubMed] [Google Scholar]
- 21.Knight CG, et al. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem. 2000;275:35–40. doi: 10.1074/jbc.275.1.35. [DOI] [PubMed] [Google Scholar]
- 22.Al-Kindi A, et al. A novel mutation in DDR2 causing spondylo-meta-epiphyseal dysplasia with short limbs and abnormal calcifications (SMED-SL) results in defective intra-cellular trafficking. BMC Med. Genet. 2014;15:42. doi: 10.1186/1471-2350-15-42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ali BR, et al. Trafficking defects and loss of ligand binding are the underlying causes of all reported DDR2 missense mutations found in SMED-SL patients. Hum. Mol. Genet. 2010;19:2239–2250. doi: 10.1093/hmg/ddq103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Bargal R, et al. Mutations in DDR2 gene cause SMED with short limbs and abnormal calcifications. Am. J. Hum. Genet. 2009;84:80–84. doi: 10.1016/j.ajhg.2008.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Mansouri M, et al. Novel DDR2 mutation identified by whole exome sequencing in a Moroccan patient with spondylo-meta-epiphyseal dysplasia, short limb-abnormal calcification type. Am. J. Med. Genet. A. 2016;170A:460–465. doi: 10.1002/ajmg.a.37426. [DOI] [PubMed] [Google Scholar]
- 26.Urel-Demir G, et al. Further expansion of the mutational spectrum of spondylo-meta-epiphyseal dysplasia with abnormal calcification. J. Hum. Genet. 2018;63:1003–1007. doi: 10.1038/s10038-018-0473-4. [DOI] [PubMed] [Google Scholar]
- 27.Borochowitz Z, et al. Spondylo-meta-epiphyseal dysplasia (SMED), short limb-hand type: a congenital familial skeletal dysplasia with distinctive features and histopathology. Am. J. Med. Genet. 1993;45:320–326. doi: 10.1002/ajmg.1320450308. [DOI] [PubMed] [Google Scholar]
- 28.Langer LO, Jr., et al. Further delineation of spondylo-meta-epiphyseal dysplasia, short limb-abnormal calcification type, with emphasis on diagnostic features. Am. J. Med. Genet. 1993;45:488–500. doi: 10.1002/ajmg.1320450419. [DOI] [PubMed] [Google Scholar]
- 29.Cowling RT, et al. Discoidin domain receptor 2 germline gene deletion leads to altered heart structure and function in the mouse. Am. J. Physiol. Heart Circ. Physiol. 2014;307:H773–781. doi: 10.1152/ajpheart.00142.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Ge C, et al. Discoidin receptor 2 controls bone formation and marrow adipogenesis. J. Bone Min. Res. 2016;31:2193–2203. doi: 10.1002/jbmr.2893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kano K, et al. A novel dwarfism with gonadal dysfunction due to loss-of-function allele of the collagen receptor gene, Ddr2, in the mouse. Mol. Endocrinol. 2008;22:1866–1880. doi: 10.1210/me.2007-0310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Mohamed FF, Ge C, Binrayes A, Franceschi RT. The role of discoidin domain receptor 2 in tooth development. J. Dent. Res. 2020;99:214–222. doi: 10.1177/0022034519892563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Jacome-Galarza CE, et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature. 2019;568:541–545. doi: 10.1038/s41586-019-1105-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Zhang Y, et al. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis. Sci. Signal. 2015;8:ra31. doi: 10.1126/scisignal.2005835. [DOI] [PubMed] [Google Scholar]
- 35.Zhang Y, et al. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. J. Bone Min. Res. 2011;26:604–617. doi: 10.1002/jbmr.225. [DOI] [PubMed] [Google Scholar]
- 36.Zhao H, et al. The suture provides a niche for mesenchymal stem cells of craniofacial bones. Nat. Cell Biol. 2015;17:386–396. doi: 10.1038/ncb3139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Shi Y, et al. Gli1 identifies osteogenic progenitors for bone formation and fracture repair. Nat. Commun. 2017;8:2043. doi: 10.1038/s41467-017-02171-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ovchinnikov DA, Deng JM, Ogunrinu G, Behringer RR. Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. Genesis. 2000;26:145–146. [PubMed] [Google Scholar]
- 39.Kan C, et al. Gli1-labeled adult mesenchymal stem/progenitor cells and hedgehog signaling contribute to endochondral heterotopic ossification. Bone. 2018;109:71–79. doi: 10.1016/j.bone.2017.06.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Jing Y, et al. Chondrogenesis and osteogenesis are one continuous developmental and lineage defined biological process. Sci. Rep. 2017;7:10020. doi: 10.1038/s41598-017-10048-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Mizuhashi K, et al. Resting zone of the growth plate houses a unique class of skeletal stem cells. Nature. 2018;563:254–258. doi: 10.1038/s41586-018-0662-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Zhang M, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 2002;277:44005–44012. doi: 10.1074/jbc.M208265200. [DOI] [PubMed] [Google Scholar]
- 43.Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science. 2001;294:1708–1712. doi: 10.1126/science.1064829. [DOI] [PubMed] [Google Scholar]
- 44.Underhill TM, Dranse HJ, Hoffman LM. Analysis of chondrogenesis using micromass cultures of limb mesenchyme. Methods Mol. Biol. 2014;1130:251–265. doi: 10.1007/978-1-62703-989-5_19. [DOI] [PubMed] [Google Scholar]
- 45.Pinho S, et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J. Exp. Med. 2013;210:1351–1367. doi: 10.1084/jem.20122252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Leitinger B. Discoidin domain receptor functions in physiological and pathological conditions. Int. Rev. cell Mol. Biol. 2014;310:39–87. doi: 10.1016/B978-0-12-800180-6.00002-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Yang, H. et al. DDR2, a discoidin domain receptor, is a marker of periosteal osteoblast and osteoblast progenitors. J. Bone Miner. Metab.38, 670-677 (2020). [DOI] [PMC free article] [PubMed]
- 48.Camper L, Holmvall K, Wangnerud C, Aszodi A, Lundgren-Akerlund E. Distribution of the collagen-binding integrin alpha10beta1 during mouse development. Cell Tissue Res. 2001;306:107–116. doi: 10.1007/s004410100385. [DOI] [PubMed] [Google Scholar]
- 49.Lundgren-Akerlund E, Aszodi A. Integrin alpha10beta1: a collagen receptor critical in skeletal development. Adv. Exp. Med. Biol. 2014;819:61–71. doi: 10.1007/978-94-017-9153-3_4. [DOI] [PubMed] [Google Scholar]
- 50.Zeltz C, Gullberg D. The integrin-collagen connection–a glue for tissue repair? J. Cell Sci. 2016;129:653–664. doi: 10.1242/jcs.180992. [DOI] [PubMed] [Google Scholar]
- 51.Ono N, Ono W, Nagasawa T, Kronenberg HM. A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. Nat. Cell Biol. 2014;16:1157–1167. doi: 10.1038/ncb3067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Labrador JP, et al. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Rep. 2001;2:446–452. doi: 10.1093/embo-reports/kve094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Yeung DA, et al. Clustering, spatial distribution, and phosphorylation of discoidin domain receptors 1 and 2 in response to soluble collagen I. J. Mol. Biol. 2019;431:368–390. doi: 10.1016/j.jmb.2018.11.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Majkowska I, Shitomi Y, Ito N, Gray NS, Itoh Y. Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts. J. Biol. Chem. 2017;292:6633–6643. doi: 10.1074/jbc.M116.770057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Aszodi A, Hunziker EB, Brakebusch C, Fassler R. Beta1 integrins regulate chondrocyte rotation, G1 progression, and cytokinesis. Genes Dev. 2003;17:2465–2479. doi: 10.1101/gad.277003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Bayer, S. V. et al. DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFs. Elife. 8, e45508 (2019). [DOI] [PMC free article] [PubMed]
- 57.Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 2007;176:709–718. doi: 10.1083/jcb.200610046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Chou LY, et al. Discoidin domain receptor 1 regulates endochondral ossification through terminal differentiation of chondrocytes. FASEB J. 2020;34:5767–5781. doi: 10.1096/fj.201901852RR. [DOI] [PubMed] [Google Scholar]
- 59.Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 2010;13:133–140. doi: 10.1038/nn.2467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Ahn S, Joyner AL. Dynamic changes in the response of cells to positive hedgehog signaling during mouse limb patterning. Cell. 2004;118:505–516. doi: 10.1016/j.cell.2004.07.023. [DOI] [PubMed] [Google Scholar]
- 61.Lizen B, Claus M, Jeannotte L, Rijli FM, Gofflot F. Perinatal induction of Cre recombination with tamoxifen. Transgenic Res. 2015;24:1065–1077. doi: 10.1007/s11248-015-9905-5. [DOI] [PubMed] [Google Scholar]
- 62.Nagy, A., M. Gertsenstein, K. Vintersten, and R. Behringer. Staining frozen mouse embryo sections for {beta}-galac- tosidase (lacZ), activity. CSH Protoc. pdb.prot4726. (2007). [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.